IDH2 and astrocytoma (excluding glioblastoma): Studies in patients with lower-grade and mainly non-enhancing IDH-mutant astrocytomas also highlighted the value of dynamic FET PET parameters (i.e. TAC patterns and TTP) to independently identify patient subgroups with favourable outcome regarding PFS and OS.